Skip to main content

CREDENCE - Primary renal outcome benefit demonstrated with Canagliflozin 100mg . Published in NEJM April 14th 2019

In this double-blind, randomized trial, 'abstract of published paper' assigned patients with type 2 diabetes and

albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor,

at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular

filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area

ABCD Nationwide FreeStyle Libre Audit – New Data Deadline - 21st May 2019

This next deadline of 21st May for data submission to the ABCD nationwide FreeStyle Libre audit has been set for two reasons.  An updated analysis will be undertaken to form the data that will be presented at the  American Diabetes Association annual professional conference between June 7-11, 2019.  This analysis will then be used to write the first paper to be published from the audit.  Data collection will continue beyond this date though 21st May is an important milestone.

NDA 2018-19, Type 1 diabetes, specialist services

We are all passionate about Technology for Type 1. Taking tech forward depends on getting a comprehensive picture of Type 1 care. If every specialist Type 1 service takes part in the 2018-19 NDA (not just the pump sub-section) it can be done this year. But there are just 2 months to submit 2018-19 data. First reports expected in November. Every service can do it. Please look at the attachments below and if needs be contact your Trust for support.